Dr. Strosberg on NETTER-1 Trial Results for Midgut NETs

Jonathan R. Strosberg, MD
Published: Friday, Oct 16, 2015



Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors (NETs).

The NETTER-1 trial compared the efficacy of 177-Lu-Dotatate (Lutathera) with octreotide (Sandostatin LAR) in patients with advanced progressive disease. Results showed that the median progression-free survival (PFS), the trial's primary endpoint, improved by 80% (HR, .21). The median time-to-progression with high-dose octreotide was 8.7 months and not yet reached in the 177-Lu-Dotatate arm at a median follow-up of 18 months. Strosberg predicts that the median PFS will be at approximately 40 months.

There was a strong improvement in overall survival, the secondary endpoint, (<.018). Though these results are encouraging, it does not meet the significance threshold for a preliminary analysis of survival, Strosberg explains.

<<< View more from the 2015 NANETS Symposium



Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors (NETs).

The NETTER-1 trial compared the efficacy of 177-Lu-Dotatate (Lutathera) with octreotide (Sandostatin LAR) in patients with advanced progressive disease. Results showed that the median progression-free survival (PFS), the trial's primary endpoint, improved by 80% (HR, .21). The median time-to-progression with high-dose octreotide was 8.7 months and not yet reached in the 177-Lu-Dotatate arm at a median follow-up of 18 months. Strosberg predicts that the median PFS will be at approximately 40 months.

There was a strong improvement in overall survival, the secondary endpoint, (<.018). Though these results are encouraging, it does not meet the significance threshold for a preliminary analysis of survival, Strosberg explains.

<<< View more from the 2015 NANETS Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x